Metastatic castration-resistant prostate cancer carries one of oncology's bleakest prognoses, and the antibody-drug conjugate revolution that reshaped breast and lung cancer treatment has largely bypassed it — until now. A preclinical and early clinical investigation published in the Journal of Clinical Investigation suggests that dual receptor targeting may finally give this disease a foothold in the ADC era, while simultaneously identifying the molecular escape route tumors are likely to exploit.
The study characterized izalontamab brengitecan (BL-B01D1), a bispecific ADC that simultaneously engages epidermal growth factor receptor (EGFR) and HER3, delivering a cytotoxic payload to cells expressing either target. Multi-omics profiling of castration-resistant prostate cancer tissue revealed that EGFR and HER3 are frequently co-expressed in adenocarcinoma subtypes but are largely absent in neuroendocrine variants — a critical biomarker distinction that defines the likely responding population. The compound showed potent, target-dependent cell killing across prostate cancer cell lines, mouse xenografts, and patient-derived organoids. A clinical case report documented rapid and durable radiologic response in a patient with high EGFR/HER3-expressing mCRPC, with organoid sensitivity closely mirroring that outcome. Mechanistic work pinpointed upregulation of the efflux transporter ABCG2 as the primary driver of acquired resistance, confirmed in biopsy tissue collected at disease progression.
This research is notable for several reasons beyond the therapeutic signal itself. The identification of ABCG2-mediated efflux as a resistance mechanism is consistent with patterns seen with other topoisomerase I inhibitor payloads and provides an immediately actionable combination hypothesis. The organoid-to-patient concordance, while limited to a single case, strengthens the translational credibility of the preclinical models. Key limitations include the reliance on a single patient's clinical data, the absence of a formal cohort trial, and the inherently animal- and cell-line-heavy evidence base. This is early-stage work, but the mechanistic rigor and pre-specified resistance pathway make it incrementally more compelling than typical preclinical ADC reports.